• Ocular infections

Vigamox Generic Name & Formulations

General Description

Moxifloxacin (as HCl) 0.5%; oph soln.

Pharmacological Class


How Supplied



Store at 2°C to 25°C (36°F to 77°F). 


Mechanism of Action

The antibacterial action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV.

Vigamox Indications


Susceptible bacterial conjunctivitis.


Vigamox is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:

Corynebacterium species

Micrococcus luteus

Staphylococcus aureus

Staphylococcus epidermidis

Staphylococcus haemolyticus

Staphylococcus hominis

Staphylococcus warneri

Streptococcus pneumoniae

Streptococcus viridans group

Acinetobacter lwoffii

Haemophilus influenza

Haemophilus parainfluenzae

Chlamydia trachomatis

Vigamox Dosage and Administration

Adults and Children

Instill 1 drop 3 times daily for 7 days.

Vigamox Contraindications

Not Applicable

Vigamox Boxed Warnings

Not Applicable

Vigamox Warnings/Precautions


For topical ophthalmic use only. Discontinue if superinfection or hypersensitivity occurs. Avoid contact lenses if symptomatic. Pregnancy. Nursing mothers.

Pregnancy Considerations

No adequate and well-controlled studies in pregnant women to inform any drug-associated risks.

Nursing Mother Considerations

Systemic levels of moxifloxacin following topical ocular administration are low; it is not known whether measurable levels of moxifloxacin would be present in breastmilk. Consider the benefits to the mother vs the potential adverse effects on the breastfed child.

Pediatric Considerations

The safety and effectiveness of Vigamox have been established in all ages and is supported by controlled studies in children and neonates.

Geriatric Considerations

No overall differences in safety and effectiveness have been observed between elderly and younger patients.

Vigamox Pharmacokinetics


Half-life: 13 hours.

Vigamox Interactions

Not Applicable

Vigamox Adverse Reactions

Adverse Reactions

Conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, hyperemia, pain, pruritus, subconjunctival hemorrhage, tearing.

Vigamox Clinical Trials

Clinical Trials

In 2 randomized controlled trials, Vigamox produced clinical cures on day 5-6 in 66-69%  of patients with bacterial conjunctivitis; microbiological success rates (eradication of baseline pathogens) ranged from 84-94%.

Vigamox was evaluated in a randomized, double-masked, parallel group study of pediatric patients with bacterial conjunctivitis between birth and 31 days of age. Patients were randomly assigned to receive Vigamox or another anti-infective agent. At day 9, results showed a clinical cure rate of 80% and a microbiological eradication success rate of 92%.

Vigamox Note

Not Applicable

Vigamox Patient Counseling

Patient Counseling

Do not touch the dropper tip to any surface to avoid contamination.

Avoid contact lens wear with bacterial conjunctivitis.

Discontinue use at the first sign of rash or allergic reaction.